Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Go back to Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds| (NASDAQ: NVCT) | Delayed: 22.00 +0.62 (2.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $21.38 | 52 Week High | $ | |||
| Open | $21.27 | 52 Week Low | $ | |||
| Day High | $23.00 | P/E | N/A | |||
| Day Low | $21.06 | EPS | $ | |||
| Volume | 880,119 | |||||
